Citations (102)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Raheleh Heydari, Meghdad Abdollahpour‐Alitappeh, Faezeh Shekari & Anna Meyfour. (2021) Emerging Role of Extracellular Vesicles in Biomarking the Gastrointestinal Diseases. Expert Review of Molecular Diagnostics 21:9, pages 939-962.
Read now
Read now
Xiaobo Tang, Gengzhen Huang, Tao Zhang & Shiqing Li. (2020) Elucidation of colon-protective efficacy of diosgenin in experimental TNBS-induced colitis: inhibition of NF-κB/IkB-α and Bax/Caspase-1 signaling pathways. Bioscience, Biotechnology, and Biochemistry 84:9, pages 1903-1912.
Read now
Read now
Hai Zhang, Qing-Cuo Ren, Yan Ren, Lin Zhao, Fan Yang, Yi Zhang, Wen-Ji Zhao, Yu-Zhu Tan & Xiao-Fei Shen. (2018) Ajudecumin A from Ajuga ovalifolia var. calantha exhibits anti-inflammatory activity in lipopolysaccharide-activated RAW264.7 murine macrophages and animal models of acute inflammation. Pharmaceutical Biology 56:1, pages 649-657.
Read now
Read now
Massimo Radin, Irene Cecchi, Karen Schreiber, Simone Baldovino, Daniela Rossi, Elisa Menegatti, Dario Roccatello & Savino Sciascia. (2017) Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. Expert Opinion on Orphan Drugs 5:1, pages 55-69.
Read now
Read now
Bram Verstockt, Gert Van Assche, Séverine Vermeire & Marc Ferrante. (2017) Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opinion on Biological Therapy 17:1, pages 31-47.
Read now
Read now
Sergio Fernandez-Martinez, Xavier Cortes, Joaquín Borrás-Blasco, Antonio Gracia-Pérez & MD Elvira Casterá. (2016) Effectiveness of a systematic vaccination program in patients with autoimmune inflammatory disease treated with anti-TNF alpha drugs. Expert Opinion on Biological Therapy 16:11, pages 1317-1322.
Read now
Read now
Lieven Pouillon, Peter Bossuyt & Laurent Peyrin-Biroulet. (2016) Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opinion on Biological Therapy 16:10, pages 1277-1290.
Read now
Read now
Konstantinos Papamichael, Gerassimos J. Mantzaris & Laurent Peyrin-Biroulet. (2016) A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease. Expert Opinion on Drug Safety 15:4, pages 493-501.
Read now
Read now
Rebecca Fausel & Anita Afzali. (2015) Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists. Therapeutics and Clinical Risk Management 11, pages 63-73.
Read now
Read now
Gerassimos J. Mantzaris, Dimitrios Tsironikos, Xanthipi Tzanetakou, Eirini Grispou, Pantelis Karatzas, Ioannis Kalogeropoulos & Konstantinos Papamichael. (2015) The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy. Scandinavian Journal of Gastroenterology 50:12, pages 1451-1455.
Read now
Read now
Articles from other publishers (92)
Yeli Fan, Xinyu Wang, Ge Yan, Hongfang Gao & Min Yang. (2023)
Rectal delivery of
89
Zr-labeled infliximab-loaded nanoparticles enables PET imaging-guided localized therapy of inflammatory bowel disease
. Journal of Materials Chemistry B 11:47, pages 11228-11234.
Crossref
Crossref
Francisco José Toja-Camba, Laura García-Quintanilla, Lorena Rodríguez-Martinez, Julia Tomine, Francisco Cajade-Pascual, Carolina Feitosa, Irene Zarra-Ferro, Manuel Barreiro-De-Acosta, Jaime González-López, Cristina Mondelo-García & Anxo Fernández-Ferreiro. (2023) Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA. Pharmaceutics 15:11, pages 2615.
Crossref
Crossref
Jianheng Hao, Yuemeng Zhao, Yuxia Cao, Haijun Wang & Laixi Ji. (2023) Electroacupuncture for ulcerative colitis patients: A meta-analysis and acupoints selection study. Heliyon 9:11, pages e20789.
Crossref
Crossref
Yinfeng Zhang, Tingting Wang, Meng Sun, Yueyue Song, Xinyuan Huang, Shutian Zhang, Jun Yang & Jinfeng Zhang. (2023) Advanced Nanomedicine: Redefining Therapeutic Paradigms for Inflammatory Bowel Disease. Advanced Healthcare Materials 12:19.
Crossref
Crossref
Antonius T Otten, Hedwig H van der Meulen, Maurice Steenhuis, Floris C Loeff, Daan J Touw, Jos G W Kosterink, Henderik W Frijlink, Theo Rispens, Gerard Dijkstra, Marijn C Visschedijk & Arno R Bourgonje. (2023) Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases.
Crossref
Crossref
Chi Zhang, Yujia Hu, Yi Yuan, Jingke Guo, Henian Li, Qiaoling Li & Shutao Liu. (2023) Liposome-embedded SOD attenuated DSS-induced ulcerative colitis in mice by ameliorating oxidative stress and intestinal barrier dysfunction. Food & Function 14:9, pages 4392-4405.
Crossref
Crossref
Yan Jing, Xiaolan Liu, Jinyu Wang, Yongqiang Ma & Xiqun Zheng. (2022) Production of Corn Protein Hydrolysate with Glutamine-Rich Peptides and Its Antagonistic Function in Ulcerative Colitis In Vivo. Foods 11:21, pages 3359.
Crossref
Crossref
Ge Yan, Xinyu Wang, Yeli Fan, Jianhan Lin, Junjie Yan, Lizhen Wang, Donghui Pan, Yuping Xu & Min Yang. (2022)
Immuno-PET Imaging of TNF-α in Colitis Using
89
Zr-DFO-infliximab
. Molecular Pharmaceutics 19:10, pages 3632-3639.
Crossref
Crossref
Min Cheol Kim, Se Hyung Kim, Seong‑Joon Koh, Ji Hoon Park & Hyuk Yoon. (2022) Clinical implication of radiologic complete remission on Crohn’s Disease: Compared with endoscopic remission. European Journal of Radiology 155, pages 110469.
Crossref
Crossref
Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Saurabh Kedia, Pabitra Sahu, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Kumar, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Govind Makharia & Vineet Ahuja. (2022) Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis. Indian Journal of Gastroenterology 41:5, pages 446-455.
Crossref
Crossref
Bihui Liu, Lei Yang, Ya Wu & Xin Zhao. (2022) Protective effect of Limosilactobacillus fermentum HFY06 on dextran sulfate sodium-induced colitis in mice. Frontiers in Microbiology 13.
Crossref
Crossref
Xiu Zhang, Shengbang Wang, Wei Wang, Liumei Song, Shuo Feng, Jingping Wang, Tong Kang, Peiwen Yang, Ning Wang, Pengju Yang, Ruimin Bai, Yongping Shao & Yan Zheng. (2022) Extracellular CIRP Upregulates Proinflammatory Cytokine Expression via the NF-kappaB and ERK1/2 Signaling Pathways in Psoriatic Keratinocytes. Mediators of Inflammation 2022, pages 1-11.
Crossref
Crossref
Muhammed Okuyucu, Ufuk Avcioğlu, Tuğba Şenel & Müge Ustaoğlu. (2022) Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease. Medicine 101:35, pages e30118.
Crossref
Crossref
Feifei Han, Xia Zhao, Xiang Li, Liyuan Peng, Weilin Liu & Jianzhong Han. (2022) Bovine lactoferricin ameliorates intestinal inflammation and mucosal barrier lesions in colitis through NF-κB/NLRP3 signaling pathways. Journal of Functional Foods 93, pages 105090.
Crossref
Crossref
Yi Zhang, Ou Wang, Nan Ma, Junjie Yi, Hongying Mi & Shengbao Cai. (2021)
The preventive effect and underlying mechanism of
Rhus chinensis
Mill. fruits on dextran sulphate sodium-induced ulcerative colitis in mice
. Food & Function 12:20, pages 9965-9978.
Crossref
Crossref
María E. Prados, Adela García-Martín, Juan D. Unciti-Broceta, Belén Palomares, Juan A. Collado, Alberto Minassi, Marco A. Calzado, Giovanni Appendino & Eduardo Muñoz. (2020) Betulinic acid hydroxamate prevents colonic inflammation and fibrosis in murine models of inflammatory bowel disease. Acta Pharmacologica Sinica 42:7, pages 1124-1138.
Crossref
Crossref
Lingna Ye, Thomas P. Chapman, Zhenzhen Wen, Lang Lin, Yun Qiu, Zhanju Liu, Zhihua Ran, Jiaming Qian, Kaichun Wu, Xiang Gao, Pinjin Hu, Minhu Chen, Simon P. L. Travis & Qian Cao. (2020) Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region. Alimentary Pharmacology & Therapeutics 53:3, pages 390-399.
Crossref
Crossref
Antoine Chupin, Vittorio Perduca, Antoine Meyer, Christophe Bellanger, Franck Carbonnel & Catherine Dong. (2020) Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 52:8, pages 1289-1297.
Crossref
Crossref
Pabitra Sahu, Sudheer K. Vuyyuru, Bhaskar Kante, Ashish Agarwal, Raju Sharma, Prasenjit Das, Rajesh Panwar, Saransh Jain, Sawan Bopanna, Govind Makharia, Saurabh Kedia & Vineet Ahuja. (2020) Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India. Indian Journal of Gastroenterology 39:4, pages 388-397.
Crossref
Crossref
Natsuki Ishida, Takahiro Miyazu, Tomohiro Sugiyama, Satoshi Tamura, Takuma Kagami, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa FurutaKen Sugimoto. (2020) The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease. Medicine 99:29, pages e21226.
Crossref
Crossref
Jian Sun, Hong Chen, Juan Kan, Yarun Gou, Jun Liu, Xin Zhang, Xiaonan Wu, Sixue Tang, Rui Sun, Chunlu Qian, Nianfeng Zhang, Fuxiang Niu & Changhai Jin. (2020) Anti-inflammatory properties and gut microbiota modulation of an alkali-soluble polysaccharide from purple sweet potato in DSS-induced colitis mice. International Journal of Biological Macromolecules 153, pages 708-722.
Crossref
Crossref
Jun Yao, Ruoyu Gao, Minghan Luo, Defeng Li, Liliangzi Guo, Zichao Yu, Feng Xiong, Cheng Wei, Benhua Wu, Zhenglei Xu, Dingguo Zhang, Jianyao Wang & Lisheng Wang. (2020) miR-802 participates in the inflammatory process of inflammatory bowel disease by suppressing SOCS5. Bioscience Reports 40:4.
Crossref
Crossref
Su Young Kim, Sejin An, Dong Kyun Park, Kwang An Kwon, Kyoung Oh Kim, Jun-Won Chung, Jung Ho Kim & Yoon Jae Kim. (2020) Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents. Therapeutic Advances in Gastroenterology 13, pages 175628482096130.
Crossref
Crossref
Vasilije Novakovic, Samire Abdija, Pia Bükmann Larsen, Mogens Fenger, Lene Gredal & Katja Kemp Jacobsen. (2019) Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels. Clinical Biochemistry 74, pages 73-75.
Crossref
Crossref
E. Yu. Chashkova, N. S. Korotayeva, E. E. Kunetsova, V. G. Gorokhova & E. V. Soboleva. (2019) Assessment of the State of Cell Membranes against the Background of Prolonged Use of Anticytokine Therapy in Patients with Ulcerative Colitis. Acta Biomedica Scientifica (East Siberian Biomedical Journal) 4:5, pages 84-90.
Crossref
Crossref
Nathalie Van den Berghe, Ann Gils & Debby Thomas. (2019) Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?. Clinical Pharmacology & Therapeutics 106:5, pages 945-954.
Crossref
Crossref
Jieun Kim, Seung Ho Kim & Tae Oh Kim. (2019) Evaluation of CT enterography findings for endoscopic complete remission after anti-TNF-α therapy in patients with Crohn’s disease. Acta Radiologica 60:10, pages 1200-1208.
Crossref
Crossref
Mayara Santa Rosa Lima, Vanessa Cristina Oliveira de Lima, Grasiela PiuvezamKesley Pablo Morais de AzevedoBruna Leal Lima MacielAna Heloneida de Araújo Morais. (2019) Mechanisms of action of molecules with anti-TNF-alpha activity on intestinal barrier inflammation. Medicine 98:39, pages e17285.
Crossref
Crossref
Niels Vande Casteele, Jenny Jeyarajah, Vipul Jairath, Brian G. Feagan & William J. Sandborn. (2019) Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 17:9, pages 1814-1821.e1.
Crossref
Crossref
Bram Verstockt, Erwin Dreesen, Maja Noman, An Outtier, Nathalie Van den Berghe, Isolde Aerden, Griet Compernolle, Gert Van Assche, Ann Gils, Séverine Vermeire & Marc Ferrante. (2019) Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates. Journal of Crohn's and Colitis 13:7, pages 864-872.
Crossref
Crossref
Dorien Van den Bossche, Dieter De Smet, Johan Debrabandere & Hilde Vanpoucke. (2019) Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab. Clinical Chemistry and Laboratory Medicine (CCLM) 57:6, pages 856-863.
Crossref
Crossref
Ying Sun, Xiaodan Shi, Xing Zheng, Shaoping Nie & Xiaojuan Xu. (2019) Inhibition of dextran sodium sulfate-induced colitis in mice by baker’s yeast polysaccharides. Carbohydrate Polymers 207, pages 371-381.
Crossref
Crossref
Panna Vass, Balázs Démuth, Edit Hirsch, Brigitta Nagy, Sune K. Andersen, Tamás Vigh, Geert Verreck, István Csontos, Zsombor K. Nagy & György Marosi. (2019) Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals. Journal of Controlled Release 296, pages 162-178.
Crossref
Crossref
Zecai Zhang, Shan Li, Hongyang Cao, Peng Shen, Jiuxi Liu, Yunhe Fu, Yongguo Cao & Naisheng Zhang. (2019) The protective role of phloretin against dextran sulfate sodium-induced ulcerative colitis in mice. Food & Function 10:1, pages 422-431.
Crossref
Crossref
Konstantinos Papamichael, Steve Lin, Matthew Moore, Garyfallia Papaioannou, Lindsey Sattler & Adam S. Cheifetz. (2019) Infliximab in inflammatory bowel disease. Therapeutic Advances in Chronic Disease 10, pages 204062231983844.
Crossref
Crossref
Mengya Zhang, Yan Zhao, Na Wu, Yao Yao, Mingsheng Xu, Huaying Du & Yonggang Tu. (2018) The anti-inflammatory activity of peptides from simulated gastrointestinal digestion of preserved egg white in DSS-induced mouse colitis. Food & Function 9:12, pages 6444-6454.
Crossref
Crossref
Colin Reardon, Kaitlin Murray & Alan E. Lomax. (2018) Neuroimmune Communication in Health and Disease. Physiological Reviews 98:4, pages 2287-2316.
Crossref
Crossref
Neeraj Narula, Farhad Peerani, Joseph Meserve, Gursimran Kochhar, Khadija Chaudrey, Justin Hartke, Prianka Chilukuri, Jenna Koliani-Pace, Adam Winters, Leah Katta, Eugenia Shmidt, Robert Hirten, David Faleck, Malav P. Parikh, Diana Whitehead, Brigid S. Boland, Siddharth Singh, Sashidhar Varma Sagi, Monika Fischer, Shannon Chang, Morris Barocas, Michelle Luo, Karen Lasch, Matthew Bohm, Dana Lukin, Keith Sultan, Arun Swaminath, David Hudesman, Nitin Gupta, Bo Shen, Sunanda Kane, Edward V. Loftus, Corey A. Siegel, Bruce E. Sands, Jean-Frederic Colombel, William J. Sandborn & Parambir S. Dulai. (2018) Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology 113:9, pages 1345.
Crossref
Crossref
Marlies Ballegeer, Kelly Van Looveren, Steven Timmermans, Melanie Eggermont, Sofie Vandevyver, Fabien Thery, Karen Dendoncker, Jolien Souffriau, Jolien Vandewalle, Lise Van Wyngene, Riet De Rycke, Nozomi Takahashi, Peter Vandenabeele, Jan Tuckermann, Holger M. Reichardt, Francis Impens, Rudi Beyaert, Karolien De Bosscher, Roosmarijn E. Vandenbroucke & Claude Libert. (2018) Glucocorticoid receptor dimers control intestinal STAT1 and TNF-induced inflammation in mice. Journal of Clinical Investigation 128:8, pages 3265-3279.
Crossref
Crossref
Samuel O. Adegbola, Kapil Sahnan, Janindra Warusavitarne, Ailsa Hart & Philip Tozer. (2018) Anti-TNF Therapy in Crohn’s Disease. International Journal of Molecular Sciences 19:8, pages 2244.
Crossref
Crossref
William T. Clarke, Shreya S. Amin, Konstantinos Papamichael, Joseph D. Feuerstein & Adam S. Cheifetz. (2018) Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg−) on anti-TNF therapy have a low rate of reactivation. Clinical Immunology 191, pages 59-62.
Crossref
Crossref
Sung Chul Park & Yoon Tae Jeen. (2018) Anti-integrin therapy for inflammatory bowel disease. World Journal of Gastroenterology 24:17, pages 1868-1880.
Crossref
Crossref
Saartje Van de Vondel, Filip Baert, Christine Reenaers, Stijn Vanden Branden, Leila Amininejad, Pieter Dewint, Wouter Van Moerkercke, Jean-François Rahier, Pieter Hindryckx, Peter Bossuyt, Marc Ferrante, F Baert, D De Wulf, L Moortgat, E De Cock, L Decaestecker, A D’Hondt, W Van Moerkercke, S Himpe, P Dewint, C Reenaers, C Van Kemzeke, E Louis, J F Rahier, L Amininejad, D Franchimont, V Wambacq, P Bossuyt, I Van de Schoot, K Asnong, S Vanden Branden, A Sterckx, P Hindryckx, M De Vos, M Ferrante, M Noman, S Vermeire, G Van Assche, D Franchimont, J -F Rahier, M Ferrante & S Vermeire. (2018) Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. Inflammatory Bowel Diseases 24:5, pages 1099-1105.
Crossref
Crossref
K. Murray & C. Reardon. (2018) The cholinergic anti‐inflammatory pathway revisited. Neurogastroenterology & Motility 30:3.
Crossref
Crossref
Wiebe Vanhove, Kris Nys, Ingrid Arijs, Isabelle Cleynen, Manuel Noben, Sebastiaan De Schepper, Gert Van Assche, Marc Ferrante & Séverine Vermeire. (2018) Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis 12:2, pages 178-187.
Crossref
Crossref
Savino Sciascia, Massimo Radin, Dario Roccatello, Giovanni Sanna & Maria Laura Bertolaccini. (2018) Recent advances in the management of systemic lupus erythematosus. F1000Research 7, pages 970.
Crossref
Crossref
Zijuan Zhou, Liang Wang, Panpan Feng, Lianhong Yin, Chen Wang, Shengxu Zhi, Jianyi Dong, Jingyu Wang, Yuan Lin, Dapeng Chen, Yongjian Xiong & Jinyong Peng. (2017) Inhibition of Epithelial TNF-α Receptors by Purified Fruit Bromelain Ameliorates Intestinal Inflammation and Barrier Dysfunction in Colitis. Frontiers in Immunology 8.
Crossref
Crossref
Niels Vande Casteele. (2017) Assays for measurement of TNF antagonists in practice. Frontline Gastroenterology 8:4, pages 236-242.
Crossref
Crossref
Sufeng Zhang, Robert Langer & Giovanni Traverso. (2017) Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. Nano Today 16, pages 82-96.
Crossref
Crossref
Iris DetrezThomas Van StappenMaría D. Martín Arranz, Kostas PapamichaelAnn Gils. (2017) Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease. Therapeutic Drug Monitoring 39:4, pages 344-349.
Crossref
Crossref
B. Bonaz, V. Sinniger & S. Pellissier. (2017) Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease. Journal of Internal Medicine 282:1, pages 46-63.
Crossref
Crossref
Mathurin Flamant, Josselin Rigaill, Stephane Paul & Xavier Roblin. (2017) Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects. Drugs 77:10, pages 1057-1068.
Crossref
Crossref
Kiichiro Tsuchiya, Ryohei Hayashi, Keita Fukushima, Shuji Hibiya, Nobukatsu Horita, Mariko Negi, Eisaku Itoh, Takumi Akashi, Yoshinobu Eishi, Satoshi Motoya, Yoshiaki Takeuchi, Reiko Kunisaki, Ken Fukunaga, Shiro Nakamura, Naoki Yoshimura, Masakazu Takazoe, Bunei Iizuka, Yasuo Suzuki, Masakazu Nagahori & Mamoru Watanabe. (2017) Caudal type homeobox 2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis. Journal of Gastroenterology and Hepatology 32:5, pages 1032-1039.
Crossref
Crossref
Mario C. Manresa & Cormac T. Taylor. (2017) Hypoxia Inducible Factor (HIF) Hydroxylases as Regulators of Intestinal Epithelial Barrier Function. Cellular and Molecular Gastroenterology and Hepatology 3:3, pages 303-315.
Crossref
Crossref
Ingrid Arijs & Isabelle Cleynen. (2017) RISK stratification in paediatric Crohn's disease. The Lancet 389:10080, pages 1672-1674.
Crossref
Crossref
Aleš Berlec, Martina Perše, Matjaž Ravnikar, Mojca Lunder, Andreja Erman, Anton Cerar & Borut Štrukelj. (2017) Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α. International Immunopharmacology 43, pages 219-226.
Crossref
Crossref
Massimo Radin, Savino Sciascia, Dario Roccatello & Maria Jose Cuadrado. (2016) Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. BioDrugs 31:1, pages 37-49.
Crossref
Crossref
Daniela Mayumi Rocha, Josefina Bressan & Helen Hermana Hermsdorff. (2017) The role of dietary fatty acid intake in inflammatory gene expression: a critical review. Sao Paulo Medical Journal 135:2, pages 157-168.
Crossref
Crossref
Bruno Bonaz, Valérie Sinniger, Sonia Pellissier & Didier Clarençon. 2017. Electroceuticals. Electroceuticals
205
230
.
Konstantinos Papamichael & Adam S Cheifetz. (2016) Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterology 7:4, pages 289-300.
Crossref
Crossref
T. Billiet, I. Cleynen, V. Ballet, M. Ferrante, G. Van Assche, A. Gils & S. Vermeire. (2016) Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience. Alimentary Pharmacology & Therapeutics 44:7, pages 673-683.
Crossref
Crossref
Jiqu Xu, Guangjing Tian, Congcong Ma, Hui Gao, Chang Chen, Wei Yang, Qianchun Deng, Qingde Huang, Zhonghua Ma & Fenghong Huang. (2016) Flaxseed lignan secoisolariciresinol diglucoside ameliorates experimental colitis induced by dextran sulphate sodium in mice. Journal of Functional Foods 26, pages 187-195.
Crossref
Crossref
Xin Chen, Yingjie Nie, Haitao Xiao, Zhaoxiang Bian, Anthony J. Scarzello, Na-Young Song, Anna L. Trivett, De Yang & Joost J. Oppenheim. (2016) TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis. Scientific Reports 6:1.
Crossref
Crossref
Konstantinos Papamichael, Oliviane Rivals-Lerebours, Thomas Billiet, Niels Vande Casteele, Ann Gils, Marc Ferrante, Gert Van Assche, Paul J. Rutgeerts, Gerassimos J. Mantzaris, Laurent Peyrin-Biroulet & Severine Vermeire. (2016) Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. Journal of Crohn's and Colitis 10:9, pages 1015-1023.
Crossref
Crossref
S.E. Russell, R.M. Horan, A.M. Stefanska, A. Carey, G. Leon, M. Aguilera, D. Statovci, T. Moran, P.G. Fallon, F. Shanahan, E.K. Brint, S. Melgar, S. Hussey & P.T. Walsh. (2016) IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal Immunology 9:5, pages 1193-1204.
Crossref
Crossref
Shuhei Tsuchiya, Keisuke Sugimoto, Masahiro Omori, Ryo Matsuda, Masahito Fujio & Hideharu Hibi. (2016) Mandibular osteomyelitis implicated in infliximab and periapical periodontitis: A case report. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 28:5, pages 410-415.
Crossref
Crossref
Cherry KimSeong Ho ParkSuk-Kyun YangByong Duk YeSang Hyoung ParkJong Seok LeeHyun Jin KimAh Young KimHyun Kwon Ha. (2016) Endoscopic Complete Remission of Crohn Disease After Anti–Tumor Necrosis Factor-α Therapy: CT Enterographic Findings and Their Clinical Implications. American Journal of Roentgenology 206:6, pages 1208-1216.
Crossref
Crossref
Michael Miligkos, Konstantinos Papamichael, Niels Vande Casteele, Gerassimos J. Mantzaris, Ann Gils, Barrett G. Levesque & Elias Zintzaras. (2016) Efficacy and Safety Profile of Anti–tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn’s Disease: A Network Meta-analysis of Indirect Comparisons. Clinical Therapeutics 38:6, pages 1342-1358.e6.
Crossref
Crossref
Eniko Nagy, Ramona M. Rodriguiz, William C. Wetsel, Nancie J. MacIver & Laura P. Hale. (2016) Reproduction and Growth in a Murine Model of Early Life-Onset Inflammatory Bowel Disease. PLOS ONE 11:4, pages e0152764.
Crossref
Crossref
Konstantinos Papamichael, Thomas Van Stappen, Niels Vande Casteele, Ann Gils, Thomas Billiet, Sophie Tops, Karolien Claes, Gert Van Assche, Paul Rutgeerts, Severine Vermeire & Marc Ferrante. (2016) Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 14:4, pages 543-549.
Crossref
Crossref
Caroline Meyer Olesen, Mehmet Coskun, Laurent Peyrin-Biroulet & Ole Haagen Nielsen. (2016) Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology & Therapeutics 159, pages 110-119.
Crossref
Crossref
Dong Il Park. (2016) Current status of biosimilars in the treatment of inflammatory bowel diseases. Intestinal Research 14:1, pages 15.
Crossref
Crossref
Giorgos Bamias, Theresa T. Pizarro & Fabio Cominelli. (2016) Pathway-based approaches to the treatment of inflammatory bowel disease. Translational Research 167:1, pages 104-115.
Crossref
Crossref
Thomas Billiet, Konstantinos Papamichael, Magali de Bruyn, Bram Verstockt, Isabelle Cleynen, Fred Princen, Sharat Singh, Marc Ferrante, Gert Van Assche & Severine Vermeire. (2015) A Matrix-based Model Predicts Primary Response to Infliximab in Crohn’s Disease. Journal of Crohn's and Colitis 9:12, pages 1120-1126.
Crossref
Crossref
Gauraang Bhatnagar, Nikolaos Dikaios, Davide Prezzi, Roser Vega, Steve Halligan & Stuart A Taylor. (2015) Changes in dynamic contrast-enhanced pharmacokinetic and diffusion-weighted imaging parameters reflect response to anti-TNF therapy in Crohn's disease. The British Journal of Radiology 88:1055, pages 20150547.
Crossref
Crossref
K. Papamichael, T. Van Stappen, V. Jairath, K. Gecse, R. Khanna, G. D'Haens, S. Vermeire, A. Gils, B. G. Feagan, B. G. Levesque & N. Vande Casteele. (2015) Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics 42:10, pages 1158-1169.
Crossref
Crossref
Valderílio Feijó Azevedo, Eduardo de Souza Meirelles, Jussara de Almeida Lima Kochen, Ana Cristina Medeiros, Sender J. Miszputen, Fábio Vieira Teixeira, Adérson Osmar Mourão Cintra Damião, Paulo Gustavo Kotze, Ricardo Romiti, Marcelo Arnone, Renata Ferreira Magalhães, Cláudia Pires Amaral Maia & André Vicente E. de Carvalho. (2015) Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease—Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases. Autoimmunity Reviews 14:9, pages 769-773.
Crossref
Crossref
Keita Fukushima, Kiichiro Tsuchiya, Yoshihito Kano, Nobukatsu Horita, Shuji Hibiya, Ryohei Hayashi, Keisuke Kitagaki, Mariko Negi, Eisaku Itoh, Takumi Akashi, Yoshinobu Eishi, Shigeru Oshima, Takashi Nagaishi, Ryuichi Okamoto, Tetsuya Nakamura & Mamoru Watanabe. (2015) Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line. Cancer Science 106:8, pages 1000-1007.
Crossref
Crossref
Ioannis E. Koutroubakis, Claudia Ramos-Rivers, Miguel Regueiro, Efstratios Koutroumpakis, Benjamin Click, Marc Schwartz, Jason Swoger, Leonard Baidoo, Jana G. Hashash, Arthur Barrie, Michael A. Dunn & David G. Binion. (2015) The Influence of Anti–tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 21:7, pages 1587-1593.
Crossref
Crossref
Steven R. Feldman. (2015) Inflammatory diseases: Integrating biosimilars into clinical practice. Seminars in Arthritis and Rheumatism 44:6, pages S16-S21.
Crossref
Crossref
Konstantinos Papamichael, Niels Vande Casteele, Ann Gils, Sophie Tops, Scott Hauenstein, Sharat Singh, Fred Princen, Gert Van Assche, Paul Rutgeerts, Severine Vermeire & Marc Ferrante. (2015) Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission. Clinical Gastroenterology and Hepatology 13:6, pages 1103-1110.
Crossref
Crossref
K. Karmiris, P. Bossuyt, D. Sorrentino, T. Moreels, A. Scarcelli, J. Legido, I. Dotan, G. D. Naismith, A. Jussila, J. C. Preiss, W. Kruis, A. C. Y. Li, G. Bouguen, H. Yanai, F. Steinwurz, K. H. Katsanos, K. Subramaniam, D. Tarabar, I. V. Zaganas & S. Ben-Horin. (2015) Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents. Journal of Crohn's and Colitis 9:5, pages 382-389.
Crossref
Crossref
S. B. Cohen & E. Y. Denkers. (2015)
The gut mucosal immune response to
Toxoplasma gondii
. Parasite Immunology 37:3, pages 108-117.
Crossref
Crossref
Niels Vande Casteele & Ann Gils. (2015) Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. The Journal of Clinical Pharmacology 55:S3, pages S39-S50.
Crossref
Crossref
Konstantinos Papamichael. (2015) Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World Journal of Gastroenterology 21:16, pages 4773.
Crossref
Crossref
TARO OSADA & SUMIO WATANABE. (2015) Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives. Juntendo Medical Journal 61:6, pages 588-596.
Crossref
Crossref
Isabelle Naegelen, Nicolas Beaume, Sébastien Plançon, Véronique Schenten, Eric J. Tschirhart & Sabrina Bréchard. (2015) Regulation of Neutrophil Degranulation and Cytokine Secretion: A Novel Model Approach Based on Linear Fitting. Journal of Immunology Research 2015, pages 1-15.
Crossref
Crossref
Roosmarijn E. Vandenbroucke & Claude Libert. (2014) Is there new hope for therapeutic matrix metalloproteinase inhibition?. Nature Reviews Drug Discovery 13:12, pages 904-927.
Crossref
Crossref
Fabian Schnitzler, Matthias Friedrich, Christiane Wolf, Marianne Angelberger, Julia Diegelmann, Torsten Olszak, Florian Beigel, Cornelia Tillack, Johannes Stallhofer, Burkhard Göke, Jürgen Glas, Peter Lohse & Stephan Brand. (2014) The NOD2 p.Leu1007fsX1008 Mutation (rs2066847) Is a Stronger Predictor of the Clinical Course of Crohn's Disease than the FOXO3A Intron Variant rs12212067. PLoS ONE 9:11, pages e108503.
Crossref
Crossref
Thomas Billiet, Marc Ferrante & Gert Van Assche. (2014) The Use of Prognostic Factors in Inflammatory Bowel Diseases. Current Gastroenterology Reports 16:11.
Crossref
Crossref
Brian G. Feagan, Denis Choquette, Subrata Ghosh, Dafna D. Gladman, Vincent Ho, Bernd Meibohm, Guangyong Zou, Zhenhua Xu, Gopi Shankar, David C. Sealey & Anthony S. Russell. (2014) The challenge of indication extrapolation for infliximab biosimilars. Biologicals 42:4, pages 177-183.
Crossref
Crossref
Romain Altwegg & Thierry Vincent. (2014) TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease. Mediators of Inflammation 2014, pages 1-7.
Crossref
Crossref